The Capecitabine Market report published by Market Data Forecast provides a detailed account of the Market Trends via Customized Research presented as Strategic Analyses, Company Profiles, Competitive Landscape, etc. According to the report the Capecitabine Market is estimated to be USD XX million in 2016 and predicted to rise to USD XX million by 2021 with a CAGR of XX%. The market is segmented by Application (Colon Cancer, Rectal Cancer, Breast Cancer, Gastric Cancer, and Others), and Drug Formulation (Tablets and Capsules). Further the market is also geographically segmented into North America, Europe, Asia-Pacific, Latin America and Middle-East & Africa.
Growth in prevalence of cancer, increase in demand for target drug therapy, and patent expiry of capecitabine drive the growth of the capecitabine market. According to the National Cancer Institute around 135,430 people are estimated to suffer from colon and rectum cancer and 50,260 people died of colon and rectum cancer in 2017 in the U.S. Furthermore, rise in healthcare expenditure and increase in investment in cancer treatment or assisted programs by governments and private organizations such as Cancer Care and Cancer Suraksha Scheme are anticipated to boost the market growth. However, high cost of capecitabine, adverse effects, presence of substitutes, such as raltitrexed and leucovorin, and stringent government regulations related to the safety and efficacy of capecitabine hinder the market growth. Ongoing R&D activities related to capecitabine are anticipated to present new opportunities for the market.
The global Capecitabine market is segmented on the basis of Application and Drug Formulation. On the basis of Application, the market is segmented into Colon Cancer, Rectal Cancer, Breast Cancer, Gastric Cancer, and Others. On the basis of Drug Formulation, the market is segmented into Tablets and Capsules.
On the basis of geography, the Capecitabine market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East and Africa. North America accounted for the largest share of the Capecitabine market followed by Europe and Asia Pacific. Asia Pacific is expected to witness the highest CAGR in the coming years.
The market is dominated by companies like Novartis AG, Sensus Healthcare, RXi Pharmaceuticals, Inc., Sonoma Pharmaceuticals, Inc., Perrigo Company plc, Bristol-Myers Squibb Company, Pacific World Corporation, Valeant Pharmaceuticals International, Inc., Revitol Corporation and Avita Medical Limited.
Browse through the full report at “https://www.marketdataforecast.com/market-reports/capecitabine-market-6413/ ” and checkout our recent reports in the Pharmaceuticals at “https://www.marketdataforecast.com/subcategory/pharmaceuticals-1/”. For more insights and up-to-date industry news don’t forget subscribing to our newsletters.